Literature DB >> 11953988

Immunogenicity of recombinant type IX collagen in murine collagen-induced arthritis.

L K Myers1, T Pihlajamaa, D D Brand, M A Cremer, M Bodo, L Ala-Kokko, A H Kang.   

Abstract

OBJECTIVE: Past attempts to isolate type IX collagen (CIX) from cartilage using limited proteolysis yielded partially degraded material. Recent application of recombinant technology, however, has allowed the preparation of intact native CIX. We used the murine collagen-induced arthritis model to characterize the immunologic properties of recombinant human CIX (rCIX) produced using a baculovirus expression system.
METHODS: A panel of B10 congenic mice was immunized with rCIX emulsified with Freund's complete adjuvant (CFA). The ability of the rCIX to induce tolerance and suppress arthritis was determined by administration intravenously or orally before challenge with CII/CFA.
RESULTS: None of the mice immunized with rCIX developed overt arthritis, although 2 of 5 HLA-DR1 transgenic mice developed limited digital erythema and swelling. Recombinant CIX administered by either route effectively induced suppression of arthritis, although the suppression was less pronounced than that induced with CII. Immune responses to CIX and CII were specific, suggesting that bystander suppression, rather than cross-reactivity with CII, was instrumental in suppressing arthritis.
CONCLUSION: These data show that CIX down-regulates arthritis in mice while having no associated risk of inducing arthritis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953988     DOI: 10.1002/art.10163

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  2 in total

1.  Auricular chondritis in NOD.DQ8.Abetao (Ag7-/-) transgenic mice resembles human relapsing polychondritis.

Authors:  Veena Taneja; Marie Griffiths; Marshall Behrens; Harvinder S Luthra; Chella S David
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

2.  Immunogenicity of intensively decellularized equine carotid arteries is conferred by the extracellular matrix protein collagen type VI.

Authors:  Ulrike Boeer; Falk F R Buettner; Melanie Klingenberg; Georgios C Antonopoulos; Heiko Meyer; Axel Haverich; Mathias Wilhelmi
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.